" class="no-js "lang="en-US"> MD Ally - Medtech Alert
Friday, October 24, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
MD Ally | Pharmtech Focus

MD Ally

About MD Ally

MD Ally

MD Ally was designed to enable an innovative EMS-provider collaboration that optimizes community-based medical services, establishes strong patient-provider relationships, and ensures great clinical and financial outcomes for the patient.

Related Story

Fundraising

 MD Ally Announces $3.5M Seed Round to Connect 9-1-1 and First Responders to Telehealth

MD Ally Announces $3.5M Seed Round to Connect 9-1-1 and First Responders to Telehealth, Mental Health and Social Services

April 28 2021

MD Ally, a 911-powered telehealth company, today announced a $3.5M seed round to expand the […]